Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0917 Synthekine ECP
BioCentury & Getty Images

Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

Modality-agnostic newco gives cytokines the GPCR treatment for cancer and autoimmunity

Stanford spinout taps structural biology from Chris Garcia’s lab to get new functions from natural cytokine receptors.

Sep 18, 2020 | 1:38 AM GMT

Synthekine is translating the structural biology work of Stanford synthetic cytokine pioneer K. Chris Garcia into a broad platform that could generate

Read the full 720 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE